Autor según el artículo: Cano A, Ettcheto M, Espina M, Auladell C, Calpena AC, Folch J, Barenys M, Sánchez-López E, Camins A, García ML.

Departamento: Bioquímica i Biotecnologia

Autor/es de la URV: Folch Lopez, Jaume

Palabras clave: Polymeric nanoparticles Plga-peg Neurodegeneration Epilepsy Epigallocatechin-3-gallate plga-peg epilepsy epigallocatechin-3-gallate

Resumen: Temporal lobe epilepsy is the most common type of pharmacoresistant epilepsy in adults. Epigallocatechin-3-gallate has aroused much interest because of its multiple therapeutic effects, but its instability compromises the potential effectiveness. PEGylated-PLGA nanoparticles of Epigallocatechin-3-gallate were designed to protect the drug and to increase the brain delivery. Nanoparticles were prepared by the double emulsion method and cytotoxicity, behavioral, Fluoro-Jade C, Iba1 and GFAP immunohistochemistry studies were carried out to determine their effectiveness. Nanoparticles showed an average size of 169 nm, monodisperse population, negative surface charge, encapsulation efficiency of 95% and sustained release profile. Cytotoxicity assays exhibited that these nanocarriers were non-toxic. Behavioral test showed that nanoparticles reduced most than free drug the number of epileptic episodes and their intensity. Neurotoxicity and immunohistochemistry studies confirmed a decrease in neuronal death and neuroinflammation. In conclusion, Epigallocatechin-3-gallate PEGylated-PLGA nanoparticles could be a suitable strategy for the treatment of temporal lobe epilepsy.

Áreas temáticas: Química Psicología Pharmaceutical science Odontología Nanoscience and nanotechnology Nanoscience & nanotechnology Molecular medicine Medicine, research & experimental Medicine (miscellaneous) Medicina veterinaria Medicina iii Medicina ii Medicina i Materials science (miscellaneous) Materials science (all) Materiais Interdisciplinar General medicine General materials science Farmacia Engenharias iv Engenharias iii Engenharias ii Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciências agrárias i Biotecnología Biomedical engineering Bioengineering Astronomia / física

Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/

ISSN: 15499634

Direcció de correo del autor: jaume.folch@urv.cat

Identificador del autor: 0000-0002-5051-8858

Fecha de alta del registro: 2023-02-18

Versión del articulo depositado: info:eu-repo/semantics/acceptedVersion

Enlace a la fuente original: https://www.sciencedirect.com/science/article/abs/pii/S1549963418300315?via%3Dihub

URL Documento de licencia: http://repositori.urv.cat/ca/proteccio-de-dades/

Referencia al articulo segun fuente origial: Nanomedicine-Nanotechnology Biology And Medicine. 14 (4): 1073-1085

Referencia de l'ítem segons les normes APA: Cano A, Ettcheto M, Espina M, Auladell C, Calpena AC, Folch J, Barenys M, Sánchez-López E, Camins A, García ML. (2018). Epigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy.. Nanomedicine-Nanotechnology Biology And Medicine, 14(4), 1073-1085. DOI: 10.1016/j.nano.2018.01.019

DOI del artículo: 10.1016/j.nano.2018.01.019

Entidad: Universitat Rovira i Virgili

Año de publicación de la revista: 2018

Tipo de publicación: Journal Publications